LRP5, SLC6A3, and SOX10 Expression in Conventional Ameloblastoma

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Cell proliferation and invasion are hallmarks of ameloblastoma, a common odontogenic tumor.
• Targeting these cellular processes is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To identify key genes and potential inhibitory drugs associated with ameloblastoma cell proliferation and invasion.
• To utilize bioinformatic analysis for uncovering therapeutic targets.

Main Methods:

• Bioinformatic analysis of gene expression data using Rstudio and ShinyGO.
• Gene ontology enrichment, network analysis (String, Cytoscape-MCODE), and survival analysis (Kaplan-Meier plots).
• Validation through RT-qPCR and immunoexpression; drug screening via DrugGeneBudger and DrugBank.

Main Results:

• Identified 204 upregulated genes, with four pathways linked to proliferation and invasion.
• SLC6A3, SOX10, and LRP5 were negatively associated with overall survival.
• RT-qPCR confirmed overexpression of SLC6A3 and SOX10; immunoexpression showed positive LRP5 and SLC6A3.
• Parthenolide and vorinostat identified as potential inhibitory drugs.

Conclusions:

• LRP5, SLC6A3, and SOX10 are implicated in ameloblastoma pathogenesis.
• Parthenolide and vorinostat represent promising candidates for novel ameloblastoma therapeutics.
• Further investigation of these genes and drugs could lead to new treatment approaches.